The University of Southampton
University of Southampton Institutional Repository

TG4010: a vaccine with a therapeutic role in cancer

TG4010: a vaccine with a therapeutic role in cancer
TG4010: a vaccine with a therapeutic role in cancer
One of the strategies to enhance immune response against tumors has been the use of vaccines against tumor-associated antigens (TAAs). MUC1 is a TAA that is overexpressed in many malignancies being linked to worse prognosis. Moreover, tumor MUC1 is hypoglycosylated revealing new epitopes that are antigenic and potential T-cell targets. TG4010 is a recombinant viral vaccine targeting MUC1, also encoding for IL-2. TG4010 has been tested in Phase I-II trials demonstrating a consistent safety profile with mild local reactions as main side effect. These studies have confirmed immune responses to the vaccine product. Clinical efficacy has been observed mainly in patients with non-small-cell lung cancer in combination with chemotherapy. Peripheral activated NK cells are currently being validated as biomarkers of response.
1750-743X
511-519
Arriola Aperribay, Edurne
aee66171-e294-42a5-95cf-feeb699e142f
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Arriola Aperribay, Edurne
aee66171-e294-42a5-95cf-feeb699e142f
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797

Arriola Aperribay, Edurne and Ottensmeier, Christian (2016) TG4010: a vaccine with a therapeutic role in cancer. Immunotherapy, 8 (5), 511-519. (doi:10.2217/imt-2016-0015). (PMID:27140406)

Record type: Article

Abstract

One of the strategies to enhance immune response against tumors has been the use of vaccines against tumor-associated antigens (TAAs). MUC1 is a TAA that is overexpressed in many malignancies being linked to worse prognosis. Moreover, tumor MUC1 is hypoglycosylated revealing new epitopes that are antigenic and potential T-cell targets. TG4010 is a recombinant viral vaccine targeting MUC1, also encoding for IL-2. TG4010 has been tested in Phase I-II trials demonstrating a consistent safety profile with mild local reactions as main side effect. These studies have confirmed immune responses to the vaccine product. Clinical efficacy has been observed mainly in patients with non-small-cell lung cancer in combination with chemotherapy. Peripheral activated NK cells are currently being validated as biomarkers of response.

Text
TG4010.pdf - Version of Record
Restricted to Registered users only
Download (1MB)
Request a copy

More information

Accepted/In Press date: 1 March 2016
Published date: May 2016
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 396162
URI: http://eprints.soton.ac.uk/id/eprint/396162
ISSN: 1750-743X
PURE UUID: 2e407abf-22d6-4d77-a52b-040d9c7c40fa

Catalogue record

Date deposited: 07 Jun 2016 09:21
Last modified: 09 Dec 2019 19:36

Export record

Altmetrics

Contributors

Author: Edurne Arriola Aperribay

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×